Pancreatic Cancer Research

ResearcherChiba UniversityActive in the last 2 years

Koji Miyabayashi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4588-2575; OpenAlex author ID A5081664204. Sources: OpenAlex.

Their work

Papers
35
Trials
0
Grants
0
Labs led
0
Collaborators
88
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 8 papers · 2014: 4 papers · 2015: 3 papers · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 4 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 4 papers · 2026: 1 paper

Papers 35

  1. Blocking L-carnitine synthesis by meldonium prolongs the survival in mice with pancreatic cancer. Co-author DOI 10.1016/j.isci.2026.117071↗
  2. Association between homologous recombination deficiency and time to treatment failure to platinum-based chemotherapy for pancreatic cancer by using the C-CAT d… Co-author DOI 10.1007/s00535-024-02173-0↗
  3. WWP1 inhibition suppresses the proliferation of pancreatic cancer cells by regulating the PI3K-AKT pathway. Co-author DOI 10.1007/s00535-024-02192-x↗
  4. Factors associated with actionable gene aberrations in pancreatic cancer based on the C-CAT database. Co-author DOI 10.1007/s00535-025-02253-9↗
  5. Blockade of CC chemokine receptor 2 suppresses pancreatic cancer progression through the interaction with macrophages in the tumor microenvironment. Co-author DOI 10.1038/s41598-025-32222-4↗
  6. A TEAD2-Driven Endothelial-Like Program Shapes Basal-Like Differentiation and Metastasis of Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2023.02.049↗
  7. The Role of the Microbiome in Pancreatic Cancer. Co-author DOI 10.3390/cancers14184479↗
  8. Molecular and Phenotypic Profiling for Precision Medicine in Pancreatic Cancer: Current Advances and Future Perspectives. Co-author DOI 10.3389/fonc.2021.682872↗
  9. Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer. Co-author DOI 10.1038/s41598-020-78320-3↗
  10. Detection of incipient pancreatic cancer with novel tumor-specific antibodies in mouse models Co-author DOI 10.1101/2020.09.10.292193↗
  11. Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes. Co-author DOI 10.1158/2159-8290.cd-20-0133↗
  12. Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation. Co-author DOI 10.7554/elife.53381↗
  13. Blocking CXCLs-CXCR2 axis in tumor-stromal interactions contributes to survival in a mouse model of pancreatic ductal adenocarcinoma through reduced cell invas… Co-author DOI 10.1038/s41389-018-0117-8↗
  14. TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.celrep.2018.10.051↗
  15. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-18-0349↗
  16. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Co-author DOI 10.1016/j.cell.2017.07.007↗
  17. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. Co-author DOI 10.18632/oncotarget.11129↗
  18. The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. Co-author DOI 10.1007/s00432-014-1873-2↗
  19. Pancreatic cancer with malignant ascites: clinical features and outcomes. Co-author DOI 10.1097/mpa.0000000000000290↗
  20. [IPMN and pancreatic cyst as high risk of pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.112.1474↗
  21. A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. Co-author DOI 10.1007/s00280-014-2563-0↗
  22. Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. Co-author DOI 10.1007/s12029-014-9603-1↗
  23. Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPα. Co-author DOI 10.1093/carcin/bgu136↗
  24. Smoking, family history of cancer, and diabetes mellitus are associated with the age of onset of pancreatic cancer in Japanese patients. Co-author DOI 10.1097/mpa.0000000000000158↗
  25. Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monoth… Co-author DOI 10.1007/s00280-012-1981-0↗
  26. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer. Co-author DOI 10.1007/s00280-013-2278-7↗
  27. A retrospective analysis of early CA19‑9 change in salvage chemotherapy for refractory pancreatic cancer. Co-author DOI 10.1007/s00280-013-2313-8↗
  28. Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age. Co-author DOI 10.1007/s00535-012-0622-z↗
  29. A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Co-author DOI 10.1007/s10637-013-9972-5↗
  30. Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic cancer. Co-author DOI 10.1016/j.pan.2013.03.013↗
  31. Risk for mortality from causes other than pancreatic cancer in patients with intraductal papillary mucinous neoplasm of the pancreas. Co-author DOI 10.1097/mpa.0b013e318270ea97↗
  32. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. Co-author DOI 10.1158/0008-5472.can-12-1453↗
  33. Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. Co-author DOI 10.1007/s00535-011-0482-y↗
  34. Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1. Co-author DOI 10.1111/j.1349-7006.2012.02311.x↗
  35. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci42754↗

Closest collaborators

The 25 strongest of 88 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hideaki Ijichi · 25 shared papers, 2011–2026 · strength 1.77
  2. Mitsuhiro Fujishiro · 6 shared papers, 2022–2026 · strength 1.39
  3. Yousuke Nakai · 20 shared papers, 2012–2025 · strength 1.01
  4. Naminatsu Takahara · 14 shared papers, 2013–2025 · strength 0.76
  5. Kazuhiko Koike · 21 shared papers, 2011–2020 · strength 0.76
  6. Hiroyuki Isayama · 20 shared papers, 2012–2020 · strength 0.73
  7. Tsuyoshi Hamada · 12 shared papers, 2013–2025 · strength 0.71
  8. Keisuke Yamamoto · 14 shared papers, 2012–2025 · strength 0.70
  9. Makoto Sano · 4 shared papers, 2019–2026 · strength 0.68
  10. Gen Kimura · 3 shared papers, 2020–2026 · strength 0.60
  11. Takahiro Kishikawa · 3 shared papers, 2015–2025 · strength 0.54
  12. David Arthur Tuveson · 6 shared papers, 2017–2023 · strength 0.54
  13. Genso Notoya · 2 shared papers, 2025 · strength 0.51
  14. Dai Mohri · 14 shared papers, 2011–2020 · strength 0.48
  15. Minoru Tada · 15 shared papers, 2012–2015 · strength 0.46
  16. Kazunaga Ishigaki · 4 shared papers, 2015–2025 · strength 0.45
  17. Ryota Takahashi · 4 shared papers, 2016–2025 · strength 0.45
  18. Suguru Mizuno · 14 shared papers, 2012–2015 · strength 0.43
  19. Hirofumi Kogure · 14 shared papers, 2012–2015 · strength 0.43
  20. Takashi Sasaki · 14 shared papers, 2012–2015 · strength 0.43
  21. Yurie Tokito · 2 shared papers, 2025 · strength 0.38
  22. Tatsunori Suzuki · 2 shared papers, 2025 · strength 0.38
  23. Go Endo · 2 shared papers, 2025 · strength 0.38
  24. Hiroki Oyama · 2 shared papers, 2025 · strength 0.38
  25. Hidenori Kage · 2 shared papers, 2025 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.